Login / Signup

Valproate pregnancy prevention scheme: what are the barriers to enrolling patients and how do we meet them?

Musa Mamman WatilaAlistair JamesKaren MilneGraham Mackay
Published in: BMJ neurology open (2023)
A significant proportion of women continue valproate treatment without meeting the PPP requirement. This is linked to their indication for prescription and their comorbidities. Collaborative input from relevant specialities and primary care is required to fully achieve PPP if a national valproate database is to be established.
Keyphrases
  • primary care
  • end stage renal disease
  • quality improvement
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • pregnancy outcomes
  • adipose tissue
  • replacement therapy
  • insulin resistance
  • smoking cessation